John Sourbeer
Stock Analyst at UBS
(0)
# 4611
Out of 5,288 analysts
50
Total ratings
30.77%
Success rate
-16.88%
Average return
Main Sectors:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
CryoPort | Upgrades: Buy | 10 | 6.24 | 60.26% | 5 | Mar 24, 2025 | |
Stevanato Group | Maintains: Neutral | 24 24 | 21.25 | 10.59% | 2 | Mar 7, 2025 | |
QuidelOrtho | Maintains: Neutral | 43 45 | 35.41 | 27.08% | 3 | Feb 13, 2025 | |
Qiagen | Maintains: Neutral | 50 48 | 39.69 | 20.94% | 4 | Feb 7, 2025 | |
West Pharmaceutical ... | Upgrades: Buy | 350 390 | 225.81 | 72.71% | 3 | Dec 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 2 | 1.31 | 52.67% | 3 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 133 145 | 87.68 | 65.37% | 3 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 12 15 | n/a | n/a | 2 | Mar 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 452 480 | 324 | 48.15% | 4 | Mar 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 7 8 | 1.54 | 387.01% | 2 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Strong Buy | 94 102 | 43.25 | 135.84% | 3 | Mar 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 58 64 | n/a | n/a | 6 | Feb 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 7 3 | n/a | n/a | 2 | Oct 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Neutral | 50 | 9.76 | 412.3% | 1 | Feb 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Neutral | 68 | n/a | n/a | 1 | Sep 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 270 | 179.1 | 50.75% | 1 | Sep 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 142 128 | 125.46 | 2.02% | 2 | Jul 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 13 4 | n/a | n/a | 2 | Mar 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 23 | n/a | n/a | 1 | Feb 22, 2021 |